The Department of Energy’s Oak Ridge National Laboratory announced the establishment of its Center for AI Security Research, or CAISER, to address threats...
Topline results from Small Pharma's Phase Ib study exploring the interaction between SSRIs and SPL026, the company’s DMT drug. The post Positive Data...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
–Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase...
This has been a busy quarter for the psychedelic industry, particularly Lucy Scientific Discovery Inc. The company has announced three acquisitions in...
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,... The post Glancy Prongay...
In November 2022, Lusaris Therapeutics made news for its $60 million Series A round. Since then, there has been a curious silence from the company. We...
An online survey published in the International Journal of Mental Health and Addiction found that after beginning psychedelic use, many adults reduced...
Legal psychedelics are closer than ever to becoming a reality in California. Senator Scott Weiner has been trying to push a psychedelic bill through the...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed. The post News...